Navigation Links
ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Date:5/7/2009

terialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will be unable to consummate a strategic transaction on a timeline it believes is acceptable, divests its assets on best-available terms and entirely winds-down its operations; the risk that ADVENTRX will be unable to consummate a strategic or partnering transaction or otherwise raise sufficient capital and will be unable to continue as a going concern, including as a result of negative perceptions of the data from its bioequivalence study of ANX-514; the risk that ADVENTRX's recent cost-containment measures, including the discontinuation of substantially all of its development activities and fundamental business operations and reduction in force to a small, select number of full-time employees, will negatively impact ADVENTRX's ability to consummate a strategic transaction; the potential for regulatory authorities to require additional preclinical and/or clinical activities to support regulatory filings, including prior to the submission or the approval of an NDA for ANX-514, and the impact of increased uncertainty regarding the need for such activities on strategic, partnering and capital-raising transactions; the risk that the performance of third parties on whom ADVENTRX relies to conduct its studies or evaluate the data, including clinical investigators, expert data monitoring committees, contract laboratories and contract research organizations, may be substandard, or they may fail to perform as expected; difficulties or delays in obtaining regulatory approval for ANX-514, including validating commercial manufacturers and suppliers and the potential for automatic injunctions regarding FDA approval of ANX-514 and other challenges by patent holders during the Section 505(b)(2) process; the risk t
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
2. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
3. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
4. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
5. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
8. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
9. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
10. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... April 28, 2015   GenSpera, Inc. ... and Trademark Office has issued U.S. Patent No. ... claiming numerous compositions for the company,s prodrugs designed ... GenSpera is developing a series ... powerful cytotoxin isolated from the poisonous plant, ...
(Date:4/28/2015)... , April 28, 2015  Unfors RaySafe, the ... new radiation Survey sensor aimed at expanding the RaySafe ... X2 Survey sensor is the easiest and fastest solution ... It is the latest addition to the continually expanding ... to perform leakage and scatter measurements in diagnostic X-ray ...
(Date:4/28/2015)... 2015 /CNW/ - The group representing the living victims of ... a two-hour meeting with Health Canada officials in a ... Canada announced a $180 million support package for Thalidomide ... after the Health Canada announcement and five months after ... victims, the group representing Canada,s ...
Breaking Medicine Technology:GenSpera Granted New Patent for Prodrugs Activated by Prostate Specific Antigen 2Unfors RaySafe, a Fluke Biomedical company, unveils a new Survey sensor for the RaySafe X2 2Thalidomide Victims Gravely Concerned by Health Canada's Silence 2
... AAHC Calls for National Entity to Address Workforce ... center CEOs told congressional staff and representatives of ... that pending health reform legislation does not yet ... to implement successful health system reform. "Pending ...
... AMN Healthcare Services, Inc. (NYSE: AHS ), the ... its quarterly conference call to discuss third quarter results on ... company also expects to issue an earnings news release on ... approximately 4:00 p.m. Eastern Time. , A live webcast of ...
Cached Medicine Technology:Health Reform Bills Still Lack Strategic Focus on Health Workforce 2AMN Healthcare Services to Host 2009 Third Quarter Earnings Conference Call on Thursday, October 29, 2009 2
(Date:4/28/2015)... Santa Cruz, California (PRWEB) April 28, 2015 ... leader in premium, healthy, and convenient nutrition ... expansion of its distribution through United Natural ... distributor of natural, organic and specialty foods ... will now be available to thousands of ...
(Date:4/27/2015)... Churchview Supportive Living, a Gardant affordable ... and Fashion Show from 10:30 a.m. to noon on ... 2626 W. 63rd St. in Chicago, serves low-income older ... to maintain their independence. , “Mothers, grandmothers, godmothers and ... Day Brunch,” said Director of Marketing Elizabeth Clippard. , ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Women may ... from concussion, according to a new study published online ... mild traumatic brain injury (MTBI), is a common medical ... some individuals. , In most cases, patients who ... Ten to 15 percent of MTBI patients will continue ...
(Date:4/27/2015)... 2015 Jesse L. Goodman, M.D., M.P.H., ... Pharmacopeial Convention (USP) at the recently concluded Convention Meeting ... at Georgetown University and the Director of its Center ... As USP President, a volunteer position, Dr. Goodman will ... be a voting member, ex officio, of the Board ...
(Date:4/27/2015)... 27, 2015 Based in the Twin ... one of the few insurance marketing organizations in the ... and asset protection markets as well as employer sponsored ... afforded Secura Consultants the opportunity to consult with disability ... business easier and quicker. , An example of these ...
Breaking Medicine News(10 mins):Health News:LifeAID Beverage Co. Announces Expanded Distribution Roll Out Through UNFI -- United Natural Foods Inc. 2Health News:LifeAID Beverage Co. Announces Expanded Distribution Roll Out Through UNFI -- United Natural Foods Inc. 3Health News:Churchview Supportive Living Community in Chicago to Host Mother's Day Brunch 2Health News:Women Show Persistent Memory Impairment after Concussion 2Health News:Women Show Persistent Memory Impairment after Concussion 3Health News:Dr. Jesse Goodman Elected President of the USP Convention 2Health News:Simplified Solutions Now Makes Disability Insurance Business With Secura Consultants Even Easier! 2
... A recent research has found that the asthma epidemic in ... by adults over the past century . ,The study, ... is published this month in Annals of Allergy, Asthma & ... Asthma and Immunology (ACAAI). ,The pervasiveness of asthma ...
... a woman's reproductive history to start hormone therapy? How does ... is the most beneficial form of estrogen? ,These ... University of Wisconsin School of Medicine and Public Health hope ... of its kind, on the effects of estrogen therapy with ...
... tests using gene sequencing is able to help confirm ... the tools for much more accurate and rapid diagnosis. ... 40 inherited and potentially life-threatening disorders that cause enzymes ... to the accumulation of waste products that damage organs ...
... College London refutes the long-standing "runaway" theory on how HIV ... attacking T helper cells, a class of white blood cells ... long been puzzled as to why this process of depletion ... ,According to the "runaway" hypothesis, T cells infected ...
... documented the first case of virgin birth in cartilaginous fish, after ... aquarium, that had only female sharks which had no contact ... of the pup at Omaha's Henry Doorly Zoo, in the US, ... in one of the female sharks in the aquarium. ...
... Club of Calcutta will reach out to more poor people ... ,"All the three healthcare units we have opened in ... set a target to reach out to more number of ... functionary K.N. Gupta told a press conference Tuesday. ...
Cached Medicine News:Health News:Rise in Cigarette Use may Elucidate Asthma Epidemic in Children 2Health News:Effectiveness of Hormone Therapy During Menopause 2Health News:New DNA Tests Advances Treatment of Lysosomal Storage Diseases 2Health News:Study Refutes Theory on HIV's Effect on White Blood Cells 2
... as bone Gla protein, is a vitamin ... major component of the noncollagenous bone matrix ... bone, with a small amount produced by ... During bone formation, newly synthesized osteocalcin is ...
... Human Insulin-like growth factor binding protein-2 (IGFBP-2) ... IGFBPs have been proposed) which specifically bind ... IGF-II. The binding affinity of IGFBP-2 for ... than for IGF-I [1], suggesting a role ...
... produced in the adrenal gland and gonads, ... and estrone, both of which may be ... weak androgenic activity, estimated at ~(less than ... However, serum androstenedione levels often exceed testosterone ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
Medicine Products: